– First patient dosed with combination of IDE397, the IDEAYA MAT2A inhibitor, and AMG 193, the Amgen MTA-cooperative PRMT5 inhibitor, in Amgen-sponsored Phase 1/2 clinical trial – Global clinical trial will evaluate IDE397 and AMG 193 combination as potential first-in-class synthetic…
News Ticker
- [ October 3, 2023 ] City of Hope Opens First U.S. Multicenter Clinical Trial for Robotic Single-Port Mastectomies for Breast Cancer Patients Los Angeles Biotech News
- [ October 3, 2023 ] Sr Biostatistician – Glaukos Corporation – Aliso Viejo, CA Los Angeles Biotech Jobs
- [ October 3, 2023 ] Leaniar LLC Attains UiPath Platinum Partner Status, Pioneering Automation in Healthcare, Manufacturing, Supply Chain, and E-Commerce Los Angeles Biotech News
- [ October 3, 2023 ] Serimmune Announces Use of Its SERA Platform in Study Designed to Identify Features of Long COVID Through Immune Profiling Los Angeles Biotech News
- [ October 3, 2023 ] ImmPACT Bio to Present at Cell & Gene Meeting on the Mesa Los Angeles Biotech News
Copyright © 2023 Biotech Networks, LLC
